ArticleClinical pharmacology : advances and applications2014
Parkinson's disease: carbidopa, nausea, and dyskinesia.
Article in Clinical pharmacology : advances and applications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.British journal of clinical pharmacology · 2018Trial
- Review
- Selective and competitive inhibition of kynurenine aminotransferase 2 by glycyrrhizic acid and its analogues.Scientific reports · 2019Article
- Improvement of kynurenine aminotransferase-II inhibitors guided by mimicking sulfate esters.PloS one · 2018Article
- Inhibition of human kynurenine aminotransferase isozymes by estrogen and its derivatives.Scientific reports · 2017Article
- Study of the Activity and Possible Mechanism of Action of a Reversible Inhibitor of Recombinant Human KAT-2: A Promising Lead in Neurodegenerative and Cognitive Disorders.Molecules (Basel, Switzerland) · 2016Article
- Parkinson's disease managing reversible neurodegeneration.Neuropsychiatric disease and treatment · 2016Article
Corrections and comments
- Retraction · 2021-03-03Cites Retracted Work · Concerns/Issues about Data · Concerns/Issues about Image · Investigation by Journal/Publisher · Unreliable Results and/or Conclusions · Upgrade/Update of Prior Notice(s) ·
- Expression of concern · 2020-04-23Concerns/Issues about Referencing/Attributions · Conflict of Interest · Investigation by Journal/Publisher · Updated to Retraction ·
- Expression of concern
- Retracted
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When l-dopa use began in the early 1960s for the treatment of Parkinson's disease, nausea and reversible dyskinesias were experienced as continuing side effects. Carbidopa or benserazide was added to l-dopa in 1975 solely to control nausea. Subsequent to the increasing use of carbidopa has been the recognition of irreversible dyskinesias, which have automatically been attributed to l-dopa. The research into the etiology of these phenomena has identified the causative agent of the irreversible dyskinesias as carbidopa, not l-dopa. The mechanism of action of the carbidopa and benserazide causes irreversible binding and inactivation of vitamin B6 throughout the body. The consequences of this action are enormous, interfering with over 300 enzyme and protein functions. This has the ability to induce previously undocumented profound antihistamine dyskinesias, which have been wrongly attributed to l-dopa and may be perceived as irreversible if proper corrective action is not taken.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.